CSF1R and neoplasm: To explore how trametinib treatment reduces the number of CSF-1R+ cells and increases the infiltration ability and activation of CD8+ T cells, we initially used a publicly available database of single-cell RNA sequencing of HNC patients to examine whether CSF-1, the ligand of CSF-1R, is expressed by tumor cells.